Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,538.23
(
0.88%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.99
(
-0.73%
)
Bitcoin
81,155.21
(
0.83%
)
News Focus
News Focus
Post# of 6105
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 4604

Thursday, 07/31/2025 11:25:49 AM

Thursday, July 31, 2025 11:25:49 AM

Post# of 6105
ABBV 2Q25 Mavyret sales=$375M, +23% QoQ, +2% YoY:

https://investors.abbvie.com/static-files/a3a87cb9-4571-48a0-aa85-d355ae65a371

The FDA approved Mavyret for acute HCV on 6/11/25, so 2Q25 included only 2.5 weeks of the expanded label. Hence, the knock-on effects of the expanded label described in #msg-176309105 have not fully kicked in yet.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ENTA News
More ENTA News